組織金屬蛋白酶抑制因子3(TIMP3)活性蛋白
Active Tissue Inhibitors Of Metalloproteinase 3 (TIMP3)
SFD; TIMP Metallopeptidase Inhibitor 3; Metallopeptidase Inhibitor 3; Sorsby Fundus Dystrophy; Pseudoinflammatory
- 編號APA129Bo01
- 物種Bos taurus; Bovine (Cattle,牛)相同的名稱,不同的物種。
- 緩沖液成份100mM NaHCO3, 500mM NaCl緩沖液(pH8.3,含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300)
- 性狀凍干粉
- 純度> 90%
- 等電點9.4
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載英文說明書 中文說明書
- 規(guī)格10μg50μg200μg1mg5mg
- 價格暫無報價暫無報價暫無報價暫無報價暫無報價
- 欲了解實際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
活性實驗
Tissue Inhibitors of Metalloproteinase 3 (TIMP3) is a key extracellular matrix protein encoded by the TIMP3 gene, playing pivotal roles in regulating matrix metalloproteinase (MMP) activity. It is widely expressed in various tissues, participating in tissue remodeling, angiogenesis, and inflammation. Dysregulation of TIMP3 is linked to multiple diseases, including cancer, cardiovascular disorders, and degenerative conditions, due to its ability to inhibit MMP-mediated extracellular matrix degradation. TIMP3 binds specifically to MMP9 with high affinity, forming a stable complex that potently suppresses MMP9’s proteolytic activity to maintain tissue homeostasis.Thus a functional ELISA assay was conducted to detect the interaction of recombinant cattle TIMP3 and recombinant human MMP9. Briefly, TIMP3 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to MMP9-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-TIMP3 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 μL stop solution to the wells and read at 450/630nm immediately. The binding activity of recombinant cattle TIMP3 and recombinant human MMP9 was shown in Figure 1, the EC50?for this effect is 0.83911μg/mL.
用法
Reconstitute in 100mM NaHCO3, 500mM NaCl (pH8.3) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月,-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲,損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種:Bos taurus; Bovine (Cattle,牛) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
| RPA129Bo02 | 組織金屬蛋白酶抑制因子3(TIMP3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA129Bo02 | 組織金屬蛋白酶抑制因子3(TIMP3)活性蛋白 | Cell?culture;?Activity?Assays. |
| APA129Bo01 | 組織金屬蛋白酶抑制因子3(TIMP3)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPA129Bo01 | 組織金屬蛋白酶抑制因子3(TIMP3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA129Bo01 | 組織金屬蛋白酶抑制因子3(TIMP3)多克隆抗體 | IHC |
| PAA129Bo02 | 組織金屬蛋白酶抑制因子3(TIMP3)多克隆抗體 | ICC/IF |
| MAA129Bo21 | 組織金屬蛋白酶抑制因子3(TIMP3)單克隆抗體 | WB; IHC; ICC; IP. |
| SEA129Bo | 組織金屬蛋白酶抑制因子3(TIMP3)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCA129Bo | 組織金屬蛋白酶抑制因子3(TIMP3)檢測試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMA129Bo | 組織金屬蛋白酶抑制因子3(TIMP3)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| Neuroimmunomodulation | Upregulated Expression of Matrix Metalloproteinases and Tissue Inhibitors of Matrix Metalloproteinases in BALB/c Mouse Brain Challenged with Japanese Encephalitis Virus[Pubmed: source] |
| Experimental Biology and Medicine | Acidic pH conditions mimicking degenerative intervertebral discs impair the survival and biological behavior of human adipose-derived mesenchymal stem cells[Rsmjournals: Source] |
| PLoS ONE | A Combinatorial Relative Mass Value Evaluation of Endogenous Bioactive Proteins in Three-Dimensional Cultured Nucleus Pulposus Cells of Herniated Intervertebral Discs: Identification of Potential Target Proteins for Gene Therapeutic Approaches[Plosone: Source] |
| Physiol. Res. | The unwounded skin remodeling in animal models of diabetes types 1 and 2.[Pubmed: 24020818] |
| VirusDisease | Circulating levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases during Japanese encephalitis virus infection[Pubmed:26925446] |
| Acta Pharmacol Sin. | Pharmacological evidence: a new therapeutic approach to the treatment of chronic heart failure through SUR2B/Kir6.1 channel in endothelial cells.[pubmed:27890915] |
| Biochemical genetics | Comparison of Selected Protein Levels in Tumour and Surgical Margin in a Group of Patients with Oral Cavity Cancer[pubmed:28421310] |
| International Journal of Cancer | Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma[Pubmed: 30650187] |
| J. Pers. Med | Altered TIMP-3 Levels in the Cerebrospinal Fluid and Plasma of Patients with Alzheimer's Disease[Pubmed:35629249] |



